News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Heron Therapeutics, Inc. (APPA) Initiates Phase 3 Label Expansion Study Of SUSTOL™



3/31/2014 7:58:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy. This Phase 3 clinical trial will evaluate SUSTOL for the prevention of delayed-onset CINV in patients receiving highly emetogenic chemotherapy (HEC) agents and is designed to support expansion of the expected label for SUSTOL in the delayed-onset HEC setting.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES